Skip to main content
AmgenLinkedIn

Amgen announces late-breaking Phase 3 Sjögren's disease study results at ACR Convergence.

Source: Autobound Signal API · 83 signals tracked for Amgen · updated

Get Amgen's live signals in Claude or ChatGPT, or by API

AskWhat changed at Amgen this week? Use Autobound signals for amgen.com.

Source

LinkedInNov 11, 2026
likes
282
comments
8

Post

Today at the American College of Rheumatology Convergence, Amgen announced late-breaking positive results from a Phase 3 study exploring its investigational CD40L antagonist fusion protein in patients with Sjögren’s disease. Sjögren’s disease is a heterogeneous autoimmune disease in which people can experience persistent dryness, fatigue and pain, often alongside systemic involvement that can be progressive and affect daily life. We look forward to connecting with the rheumatology community to discuss these results and the ongoing needs of people living with the disease. Learn more: https://amgen.ly/4BWqWqw #ACR26

linkedin.com/posts/amgen_acr26-activity-7526269718564081664-IPYvRead the full source

Extracted by Autobound

From the Signal API record
Signal
LinkedIn

What this signalsCompany posts often show what the team is pushing right now.

More LinkedIn signals at other companies

The full record

From the Signal API record

Topics and mentions

Tags

  • Medical Research
  • Pharmaceuticals
  • Events

Initiatives

  • ACR Convergence study results presentation

Extraction

Detected
Nov 11, 2026
signal_type
linkedin-post-company
signal_subtype
linkedinPost

Use this data

Get every LinkedIn signal for Amgen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Amgen this week?”

  2. Send it to your own tools

    The Signal API returns LinkedIn signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full linkedin-post-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/6946c461-76b0-4524-8034-fd0737ee86ed returns this record as JSON. POST /v1/companies/enrich returns every signal for amgen.com.

{
  "signal_id": "6946c461-76b0-4524-8034-fd0737ee86ed",
  "signal_type": "linkedin-post-company",
  "signal_subtype": "linkedinPost",
  "detected_at": "2026-11-11T13:08:52.233+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "tags": [
      "Medical Research",
      "Pharmaceuticals",
      "Events"
    ],
    "summary": "Amgen announces late-breaking Phase 3 Sjögren's disease study results at ACR Convergence.",
    "post_url": "https://www.linkedin.com/posts/amgen_acr26-activity-7526269718564081664-IPYv",
    "num_likes": 282,
    "post_text": "Today at the American College of Rheumatology Convergence, Amgen announced late-breaking positive results from a Phase 3 study exploring its investigational CD40L antagonist fusion protein in patients with Sjögren’s disease.\n \nSjögren’s disease is a heterogeneous autoimmune disease in which people can experience persistent dryness, fatigue and pain, often alongside systemic involvement that can be progressive and affect daily life.\n \nWe look forward to connecting with the rheumatology community to discuss these results and the ongoing needs of people living with the disease.\n \nLearn more: https://amgen.ly/4BWqWqw \n\n#ACR26",
    "initiatives": [
      {
        "topic": "ACR Convergence study results presentation",
        "urgency": 0.6
      }
    ],
    "posted_date": "2026-11-11T13:08:52.233Z",
    "num_comments": 8
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.